Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Naquotinib Tablet vs Capsule in EGFR+ NSCLC
NCT03082300Phase 1Terminated
- Sponsor
- Astellas Pharma
- Start
- Mar 2017
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of naquotinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Astellas Pharma. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve to Infinity and 2 more. Started Mar 2017; status: terminated.
02
Drugs
naquotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03082300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03082300.